| Literature DB >> 34745431 |
Ji Su Lee1, Jeong Jin Ahn2, Seung Jun Kim2, So Yeon Yu1, Eun Jung Koh3, Seung Hwan Kim3, Heung Sup Sung4, Jin Won Huh5, Seung Yong Hwang1.
Abstract
Over the past 6 years, acute respiratory infections have constituted an average of more than 70,000 cases in South Korea. It results in a high mortality rate in infants and the elderly with weak immunity. There are several types of respiratory viruses that invade the human respiratory tract and cause infectious disease. Reverse transcription PCR (RT-PCR) is mainly used for respiratory virus detection owing to its high sensitivity and reproducibility. In response, a multiplex real-time RT-PCR (rRT-PCR) assay was developed for the detection of influenza A and B viruses, parainfluenza viruses 1-4 (PIV1-4), human metapneumovirus, adenovirus, human rhinovirus, respiratory syncytial virus (RSV), and SARS-CoV-2. Detection ability of RT-PCR assay was confirmed by applying it to a portable device capable of point-of-care testing (POCT). Amplicons were synthesized using primer pairs and probe sets designed for each target virus, and a standard curve was constructed to confirm the limit of detection. An experiment using nasopharyngeal swab samples was conducted to understand the field applicability of the rRT-PCR assay. Detection was confirmed in most samples. This study demonstrated that rapid and accurate detection results can be obtained using the multiplex rRT-PCR based POC test, and that it is possible to detect 14 types of respiratory viruses that are generally difficult to distinguish at the same time, enabling timely treatment. Furthermore, we expect that the portable PCR device can significantly reduce the processing procedure of clinical samples before testing, which is the main disadvantage of common RT-PCR tests and can help reduce costs. © The Korean BioChip Society 2021.Entities:
Keywords: Molecular diagnosis; Point-of-care; RT-PCR; Respiratory virus; SARS-CoV-2
Year: 2021 PMID: 34745431 PMCID: PMC8564276 DOI: 10.1007/s13206-021-00037-w
Source DB: PubMed Journal: Biochip J ISSN: 1976-0280 Impact factor: 3.494
List of primer pairs and probe sets for target virus detection
| Set | Virus | Target | Name | Sequence (5´–3´) | Tm (℃) |
|---|---|---|---|---|---|
| 1 | Influenza A | M | Forward | ACAAGACCAATCCTGTCACCT | 63 |
| Reverse | TGGACAAAGCGTCTACGCT | 64 | |||
| Probe | FAM-CTCACCGTGCCCAGTGAGC-BHQ1 | 67 | |||
| Influenza B | NS & NEP | Forward | GGATCCTCAACTCACTCTTCGA | 63 | |
| Reverse | CGGTGCTCTTGACCAAATTGG | 64 | |||
| Probe | CAL Fluor Red 610-CAATTCGAGCAGCTGAAACTGCG-BHQ2 | 66 | |||
| 2 | Influenza A (H3N2) | HA | Forward | CCATGCAGTACCAAACGGAAC | 64 |
| Reverse | CACACTGAGGGTCTCCCAATAG | 64 | |||
| Probe | FAM-TGACCGAATTGAAGTTACTAATGCTACTGA-BHQ1 | 66 | |||
| Influenza A (pandemic 09, H1N1) | HA | Forward | GGGGTAGCCCCATTGCA | 64 | |
| Reverse | AGTGATTCACACTCTGGATTTCCC | 64 | |||
| Probe | CAL Fluor Red 610-TGGGTAAATGYAACATTGCTGGCTG-BHQ2 | 66–68 | |||
| 3 | PIV1 | HN | Forward | CAGGAAACCCAGACTGCAAC | 63 |
| Reverse | GCGTACAGTGTGGTTGTAGC | 63 | |||
| Probe | FAM-TGTCCGAGAGAATGCATATCAGGTGT-BHQ1 | 67 | |||
| PIV3 | HN | Forward | AGATGTATATCAACTGTGTTCAACTCC | 63 | |
| Reverse | GCCTTTGTAGTATATCCCTGGTCC | 64 | |||
| Probe | CAL Fluor Red 610-TGAAAGATCAGATTATGCATCATCAGGC-BHQ2 | 65 | |||
| 4 | PIV2 | HN | Forward | CAGGACTATGAAAACCATTTACCTAAGT | 63 |
| Reverse | GAAAGCAAGTCTCAGTTCAGCTAG | 63 | |||
| Probe | FAM-AATCAATCGCAAAAGCTGTTCAGTCA-BHQ1 | 66 | |||
| PIV4 | P | Forward | CCTGGAGTCCCATCAAAAGTAAG | 63 | |
| Reverse | GCATCTATACGAACACCTGCTC | 63 | |||
| Probe | CAL Fluor Red 610-TGTCTCAAAATTTGTTGATCAAGACAATACAAT-BHQ2 | 66 | |||
| 5 | hMPV | F | Forward | GTTGTGVGGCARTTTTCAGA | 60–64 |
| Reverse | CCTGCWGATGTYGGCATGT | 63–65 | |||
| Probe1 | FAM-AAYGCTGGAATAACACCAGCAAT-BHQ1 | 64–66 | |||
| Probe2 | FAM-AATGCAGGGATAACACCRGCAAT-BHQ1 | 66–68 | |||
| ADV | H | Forward | CCCATGGAYGAGYCCAC | 60–65 | |
| Reverse | TCRATGACGCCGCGGT | 65–67 | |||
| Probe1 | FAM- TTCGACGTSGTCMGAGTGCAC-BHQ1 | 67–69 | |||
| Probe2 | FAM- TTTGACGTGGTCCGTGTGCAC-BHQ1 | 67 | |||
| 6 | HRV | Poly | Forward | TGAGTCCTCCGGCCC | 62.2 |
| Reverse | GAAACACGGACACCCAAAGT | 62.8 | |||
| Probe1 | FAM-CTGAATGCGGCTAATCYWACCCC-BHQ1 | 65–68 | |||
| Probe2 | FAM-CTGAATGYGGCTAACCTTAACCCYG-BHQ1 | 65–69 | |||
| RSV | M | Forward | GGGCAAATATGGAAACATACGTGAA | 64 | |
| Reverse | GGCACCCATATTGTWAGTGATGC | 64 | |||
| Probe | CAL Fluor Red 610-CTTCACGAGGGCTCCACATACAC-BHQ2 | 66 | |||
| 7 | SARS-CoV-2 (RdRp) | RdRp | Forward | GATGATACTCTCTGACGATGCTGT | 64 |
| Reverse | TCTCAGTCCAACATTTTGCTTCAG | 64 | |||
| Probe | FAM-ATGCATCTCAAGGTCTAGTGGCTAG-BHQ1 | 65 | |||
| SARS-CoV-2 (N) | N | Forward | GCTTCAGCGTTCTTCGGAATG | 64 | |
| Reverse | RTCATCCAATTTGATGGCACCT | 63 | |||
| Probe | CAL FLUOR RED 610-TTGGCATGGAAGTCACACCTTCG-BHQ2 | 67 |
Fig. 1Standard curves produced by a portable PCR device. a Influenza A virus, b influenza B virus, c Flu A H3N2, d Flu A pdm09, e PIV1, f PIV3, g PIV2, h PIV4, i hMPV, j ADV, k HRV, l RSV, m SARS-CoV-2 RdRp gene, n SARS-CoV-2 N gene
Specificity test
| Sample | AMC | Bio-Rad | GENECHECKER | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |
| Influenza A virus | 29 | – | 29 | – | 28 | 1 |
| Influenza B virus | 20 | – | 20 | – | 20 | – |
| Influenza A virus (H3N2) | 19 | – | 18 | 1 | 18 | 1 |
| Influenza A virus (pandemic09) | 10 | – | 10 | – | 10 | – |
| PIV1 | 10 | – | 10 | – | 10 | – |
| PIV2 | 10 | – | 10 | – | 10 | – |
| PIV3 | 10 | – | 10 | – | 10 | – |
| PIV4 | 10 | – | 10 | – | 10 | – |
| hMPV | 29 | – | 29 | – | 29 | – |
| ADV | 30 | – | 27 | 1 | 26 | 2 |
| HRV | 9 | 1 | 9 | – | 10 | – |
| RSV | 10 | – | 10 | – | 10 | – |
| SARS-CoV-2 (RdRp gene) | 30 | – | 29 | 1 | 28 | 2 |
| SARS-CoV-2 (N gene) | 30 | – | 30 | – | 28 | 2 |
Fig. 2Overall plan of the development platform